CRBU

Insider Trades

Name	Value	Action	Price	Current Price
Kelly Timothy PChief Technology Officer $12k6.2k shares SellFeb 25, 2026 $1.93 --
Albertson Tina M.Chief Medical Officer $2.1k1.1k shares SellFeb 24, 2026 $1.96 --
Kelly Timothy PChief Technology Officer $6.2k3.1k shares SellFeb 24, 2026 $1.96 --
Khan Ruhi AhmadChief Business Officer $14k6.9k shares SellFeb 24, 2026 $1.96 --
Mcclung Barbara GChief Legal Officer $14k6.9k shares SellFeb 24, 2026 $1.96 --
Haurwitz Rachel E.Director, Officer: President And CEO $20k20k shares BuyMar 14, 2025 $1.02 --

News

globenewswire.comCaribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026globenewswire.comJun 11

globenewswire.comCaribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meetingglobenewswire.comJun 11

marketbeat.comCaribou Biosciences Says CRISPR CAR-T Is Pivotal-Ready, CB-011 Data Nearsmarketbeat.comJun 9

seekingalpha.comCaribou Biosciences, Inc. (CRBU) Presents at Jefferies Global Healthcare Conference 2026 Transcriptseekingalpha.comJun 5

Trade CRBU

About Caribou Biosciences, Inc.

Caribou Biosciences, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to pioneering genome-edited allogeneic cell therapies. These cutting-edge treatments are engineered to address both hematologic malignancies (blood cancers) and solid tumors, serving patients across the United States and internationally. Among its primary therapeutic candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy currently undergoing Phase 1 clinical trials for relapsed or refractory B cell non-Hodgkin lymphoma, and CB-011, an allogeneic anti-BCMA CAR-T cell therapy targeting relapsed or refractory multiple myeloma. Caribou Biosciences is additionally developing CB-012, an allogeneic anti-CD371 CAR-T cell therapy for relapsed or refractory acute myeloid leukemia, along with CB-020, an allogeneic CAR-NK cell therapy aimed at solid tumors. The company also maintains a collaborative agreement with AbbVie Manufacturing Management Unlimited Company for the joint advancement of CAR-T cell therapies. Founded in 2011, Caribou Biosciences' headquarters are located in Berkeley, California.

CEO: Rachel E. Haurwitz
IPO Date: Jul 23, 2021

Market Data

Open: $1.67
High: $1.69
Low: $1.57
Volume: 2.5M
Avg Volume: 1.8M
52W High: $3.54
52W Low: $1.20

Valuation

Market Cap: $163M
Enterprise Value: $178M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-112M
Revenue: $11M
Net Income: $-148M
Cash: $12M
Debt: $27M

Events

EarningsAug 11

EPS est. -0.33